{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:24:57Z","timestamp":1793294697934,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100025147","name":"Bright Research Group","doi-asserted-by":"publisher","award":["NCT03598790"],"award-info":[{"award-number":["NCT03598790"]}],"id":[{"id":"10.13039\/100025147","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","award":["NCT03370133"],"award-info":[{"award-number":["NCT03370133"]}],"id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","award":["NCT03410992"],"award-info":[{"award-number":["NCT03410992"]}],"id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016879","name":"UCB SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016879","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jaad.2025.04.038","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T03:55:41Z","timestamp":1745466941000},"page":"644-653","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial"],"prefix":"10.1016","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0084-3131","authenticated-orcid":false,"given":"Andrew","family":"Blauvelt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"Langley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Strober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akimichi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth B.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Fernandez-Pe\u00f1as","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Kavanagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"L\u00f3pez Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9my","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Hoepken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Deherder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diamant","family":"Tha\u00e7i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jaad.2025.04.038_bib1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1477-7525-4-35","article-title":"Quality of life in patients with psoriasis","volume":"4","author":"Bhosle","year":"2006","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"10.1016\/j.jaad.2025.04.038_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-027535","article-title":"Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry","volume":"9","author":"Strober","year":"2019","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.jaad.2025.04.038_bib3","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases","volume":"76","author":"Takeshita","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2025.04.038_bib4","first-page":"167","article-title":"A systematic literature review to compare quality of life in psoriasis with other chronic diseases using EQ-5D-derived utility values","volume":"6","author":"M\u00f8ller","year":"2015","journal-title":"Patient Relat Outcome Meas"},{"issue":"1","key":"10.1016\/j.jaad.2025.04.038_bib5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2340\/00015555-1193","article-title":"Patients with psoriasis feel stigmatized","volume":"92","author":"Hrehor\u00f3w","year":"2012","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"10.1016\/j.jaad.2025.04.038_bib6","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.jaad.2017.06.028","article-title":"The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events","volume":"77","author":"Egeberg","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.04.038_bib7","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jid.2017.10.024","article-title":"Risk of incident liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis: a population-based study","volume":"138","author":"Ogdie","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2025.04.038_bib8","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1038\/jid.2015.208","article-title":"Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)","volume":"135","author":"Warren","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2025.04.038_bib11","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.3389\/fimmu.2020.01894","article-title":"Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F","volume":"11","author":"Adams","year":"2020","journal-title":"Front Immunol"},{"issue":"10273","key":"10.1016\/j.jaad.2025.04.038_bib12","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet"},{"issue":"10273","key":"10.1016\/j.jaad.2025.04.038_bib13","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jaad.2025.04.038_bib14","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jaad.2025.04.038_bib15","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa2102388","article-title":"Bimekizumab versus adalimumab in plaque psoriasis","volume":"385","author":"Warren","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jaad.2025.04.038_bib16","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/bjd\/ljad035","article-title":"Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial","volume":"188","author":"Strober","year":"2023","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2025.04.038_bib17","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jaad.2023.04.063","article-title":"Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial","volume":"89","author":"Strober","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2025.04.038_bib18","doi-asserted-by":"crossref","first-page":"487","DOI":"10.36849\/JDD.2020.4957","article-title":"Importance of complete skin clearance in psoriasis as a treatment goal: Implications for patient-reported outcomes","volume":"19","author":"Blauvelt","year":"2020","journal-title":"J Drugs Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2025.04.038_bib19","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1007\/s13555-024-01261-6","article-title":"Complete skin clearance is associated with the greatest benefits to health-related quality of life and perceived symptoms for patients with psoriasis","volume":"14","author":"Augustin","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jaad.2025.04.038_bib20","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/bjd\/ljad429","article-title":"Bimekizumab safety in patients with moderate to severe plaque psoriasis: pooled data from up to three years of treatment in randomized phase 3 trials","volume":"190","author":"Gordon","year":"2024","journal-title":"Br J Dermatol"},{"issue":"20","key":"10.1016\/j.jaad.2025.04.038_bib21","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"Ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.jaad.2025.04.038_bib22","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.0022-202X.2005.23621.x","article-title":"Translating the science of quality of life into practice: what do dermatology life quality index scores mean?","volume":"125","author":"Hongbo","year":"2005","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.04.038_bib24","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jaad.2024.02.039","article-title":"Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: analysis of phase 2\/3 randomized trials","volume":"91","author":"Blauvelt","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.04.038_bib25","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jaad.2024.03.041","article-title":"Bimekizumab safety in moderate to severe plaque psoriasis: rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3\/3b trials","volume":"91","author":"Lebwohl","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2025.04.038_bib26","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/archderm.143.9.1175","article-title":"Balancing the benefits and risks of drug treatment: a stated-preference, discrete choice experiment with patients with psoriasis","volume":"143","author":"Seston","year":"2007","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.04.038_bib27","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s13555-018-0265-y","article-title":"Secukinumab is superior to ustekinumab in clearing skin in patients with moderate to severe plaque psoriasis (16-week CLARITY results)","volume":"8","author":"Bagel","year":"2018","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"9993","key":"10.1016\/j.jaad.2025.04.038_bib28","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jaad.2025.04.038_bib29","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jaad.2016.03.026","article-title":"Clinical meaningfulness of complete skin clearance in psoriasis","volume":"75","author":"Strober","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.04.038_bib30","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/jdv.15921","article-title":"Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study","volume":"34","author":"Lebwohl","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.jaad.2025.04.038_bib31","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/bjd\/ljac040","article-title":"Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials","volume":"188","author":"Langley","year":"2023","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.04.038_bib32","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s40257-020-00555-7","article-title":"Maintenance of response through up to 4 years of continuous guselkumab treatment of psoriasis in the VOYAGE 2 phase 3 study","volume":"21","author":"Reich","year":"2020","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.04.038_bib33","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jaad.2023.07.1024","article-title":"Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up","volume":"89","author":"Papp","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2025.04.038_bib34","first-page":"734","article-title":"Methods for imputing missing efficacy data in clinical trials of biologic psoriasis therapies: implications for interpretations of trial results","volume":"16","author":"Langley","year":"2017","journal-title":"J Drugs Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2025.04.038_bib35","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamadermatol.2022.1185","article-title":"Bimekizumab safety in patients with moderate to severe plaque psoriasis: pooled results from phase 2 and phase 3 randomized clinical trials","volume":"158","author":"Gordon","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2025.04.038_bib36","first-page":"706","article-title":"Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"14","author":"Papp","year":"2015","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.04.038_bib37","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40257-016-0206-4","article-title":"A clinician's guide to the diagnosis and treatment of candidiasis in patients with psoriasis","volume":"17","author":"Armstrong","year":"2016","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2025.04.038_bib38","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"issue":"8","key":"10.1016\/j.jaad.2025.04.038_bib39","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1038\/jid.2015.144","article-title":"IL-23\/IL-17A dysfunction phenotypes inform possible clinical effects from anti-IL-17A therapies","volume":"135","author":"Blauvelt","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.04.038_bib40","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jdermsci.2020.12.003","article-title":"Blockade of the IL-17 signaling pathway increased susceptibility of psoriasis patients to superficial fungal infections","volume":"101","author":"Hiruma","year":"2021","journal-title":"J Dermatol Sci"},{"issue":"9","key":"10.1016\/j.jaad.2025.04.038_bib41","first-page":"e60","article-title":"IL-17 cytokines in immunity and inflammation","volume":"2","author":"Jin","year":"2013","journal-title":"Emerg Microbes Infect"},{"issue":"6","key":"10.1016\/j.jaad.2025.04.038_bib42","first-page":"571","article-title":"Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) Errata","volume":"19","author":"Papp","year":"2020","journal-title":"J Drugs Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225006681?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225006681?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T13:13:53Z","timestamp":1762262033000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225006681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0190962225006681"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.04.038","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.04.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}